What is William Blair’s Estimate for ADPT FY2024 Earnings?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) – Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Adaptive Biotechnologies in a report released on Thursday, November 14th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($1.09) per share for the year, up from their previous estimate of ($1.17). The consensus estimate for Adaptive Biotechnologies’ current full-year earnings is ($1.10) per share. William Blair also issued estimates for Adaptive Biotechnologies’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.94) EPS.

Several other analysts have also recently commented on the company. Piper Sandler increased their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. BTIG Research lifted their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd.

Adaptive Biotechnologies Trading Down 9.0 %

NASDAQ ADPT opened at $5.08 on Monday. The firm has a market cap of $749.71 million, a price-to-earnings ratio of -3.79 and a beta of 1.45. Adaptive Biotechnologies has a 1-year low of $2.28 and a 1-year high of $6.70. The company has a 50 day moving average of $4.95 and a 200-day moving average of $4.26.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ADPT. The Manufacturers Life Insurance Company boosted its stake in shares of Adaptive Biotechnologies by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock worth $177,000 after acquiring an additional 2,710 shares during the period. Vontobel Holding Ltd. increased its position in Adaptive Biotechnologies by 30.8% during the third quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock worth $87,000 after acquiring an additional 4,000 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in Adaptive Biotechnologies in the 3rd quarter worth about $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Adaptive Biotechnologies by 29.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company’s stock valued at $131,000 after purchasing an additional 5,826 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in shares of Adaptive Biotechnologies during the third quarter worth approximately $34,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.